Exogenus Therapeutics
Kostas Alevizopoulos serves as Chief Executive Officer of APIM Therapeutics, a biotech company focused on developing the first-in-class oncology drug ATX-101. Additionally, Kostas Alevizopoulos is a Partner at Ventac Partners, providing expertise to technology-based projects in the biotech and pharma industries, and holds the position of Chief Scientific Advisor at Gerolymatos International, which specializes in OTC and medical device products. As a Strategic Advisor for Exogenus Therapeutics, Kostas Alevizopoulos offers strategic insights as part of the advisory board. Previous roles include Chief Executive Officer of Medexis SA, Chief Scientific Officer of PNG Gerolymatos SA, and Head of R&D at Apotech Corporation, among other positions. Kostas Alevizopoulos holds a Ph.D. in Molecular Biology from the University of Lausanne and a diploma in Biochemistry and Biology from the Ethnikon kai Kapodistriakon Panepistimion Athinon.
This person is not in any teams
This person is not in any offices
Exogenus Therapeutics
Exogenus Therapeutics is an innovative biotech start-up dedicated to early stage development of therapeutic tools. Using an exosome-based platform technology, Exogenus is developing biologic products for diseases with high unmet needs, such as inflammatory and autoimmune diseases. Driven by the urgency imposed by the COVID-19 pandemic, the company is currently developing solutions for the treatment of severe lung inflammation, a condition with limited treatment options and a common cause of death following SARS‑CoV‑2 infection. Contact us at team@exogenus-t.com